Story
Editas Medicine Stock Surges on Guggenheim Upgrade to Buy
Summary
Shares of the gene-editing firm Editas Medicine rallied after Guggenheim upgraded the stock to Buy from Neutral, citing the strong preclinical profile of its cholesterol therapy EDIT-401.
Shares of Editas Medicine (NASDAQ: EDIT) surged more than 7% in pre-market trading on September 23 after investment firm Guggenheim upgraded the stock to Buy from a previous Neutral rating.
The firm also initiated a $5.00 price target on the clinical-stage biotechnology company, signaling significant potential upside from its pre-market price of $3.13.
Upgrade Driven by Cholesterol Drug Potential
Guggenheim's bullish thesis is centered on EDIT-401, Editas' lead in vivo gene editing therapy designed to treat severe hypercholesterolemia. The analyst note highlighted the therapy's strong preclinical data, which underpins the firm's updated financial models for the program.
Key preclinical findings for EDIT-401 include:
- Reductions in LDL-C (low-density lipoprotein cholesterol) of more than 90%.
- Reductions in Apolipoprotein B (ApoB) of more than 70%.
AdThe therapy uses a dual-gRNA approach to upregulate LDLR expression. Guggenheim sees potential for EDIT-401 to address a significant niche market of patients with atherosclerotic cardiovascular disease who require substantial cholesterol reduction.
Near-Term Catalyst and Market Context
The upgrade comes ahead of a key clinical inflection point for Editas. The company plans to begin a Phase 1/2a clinical study for EDIT-401 in the fourth quarter of 2026. While Guggenheim acknowledged that questions remain regarding the safety and potential off-target effects of the therapy's dual double-strand break strategy, it views the risk-reward profile as favorable.
The stock's advance was a company-specific event, standing in contrast to the broader market, where major indices like the S&P 500 and NASDAQ were trading modestly lower in the pre-market session. The rally underscores investor optimism surrounding the upcoming clinical trial and the new analyst endorsement.
Read next
More on Stocks
Stifel Highlights 8 Oil and Gas Stocks Amid Sector's Financial Discipline
Investment firm Stifel has identified top exploration & production and midstream stocks, citing the energy sector's high shareholder returns, low leverage, and favorable macro environment.
Valeo Upgraded to 'Buy' by Jefferies on Strong China Orders, Margin Outlook
Jefferies raised its rating on the French auto-parts supplier to 'Buy' from 'Hold,' citing a superior order book with Chinese automakers and an expected improvement in profitability.
McDonald's Targets Mid-50% Operating Margin, Touts AI and Unit Growth in 2030 Strategy
McDonald's outlined its "McDonald's > NEXT" growth strategy, setting long-term financial goals that include a significant operating margin expansion, steady unit growth, and the deployment of generative AI to boost efficiency.
AppLovin Stock Declines as Analyst Cites Stalled Market Share Growth
AppLovin shares fell after an Edgewater Research analyst warned that the mobile ad platform's market share expansion has effectively halted, forecasting slower-than-expected revenue growth for the fourth quarter.